Gene: PLEKHA1

59338
TAPP1
pleckstrin homology domain containing A1
protein-coding
10q26.13
Ensembl:ENSG00000107679 MIM:607772 Vega:OTTHUMG00000019184 UniprotKB:Q9HB21
NG_027823.1
PubMed
0   ANCO-SNPs
ND
5   
NA (AD)  NA (ND)   (Frontal_Cortex)
9.978e-1 (AD)  4.996e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
GOPC0.941
PDS5B0.938
NECAB10.937
RASA10.937
SENP20.936
GPD1L0.935
AFTPH0.934
TTBK20.933
YPEL20.933
FGFR1OP20.933

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.525
OR4F29-0.507
LRAT-0.418
AQP5-0.416
ASB4-0.41
KLRB1-0.403
MTRNR2L10-0.4
S100A14-0.384
CSAG1-0.378
MAPKAPK3-0.374

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB04272Citric AcidSmall Molecule77-92-9Approved|NutraceuticalTarget
ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of PLEKHA1 mRNA"25510870
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of PLEKHA1 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of PLEKHA1 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of PLEKHA1 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of PLEKHA1 mRNA"25510870
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHA1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHA1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHA1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHA1 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of PLEKHA1 mRNA21420995
D000082AcetaminophenAcetaminophen affects the expression of PLEKHA1 mRNA17562736
D000082Acetaminophen[Clofibrate co-treated with Acetaminophen] affects the expression of PLEKHA1 mRNA17585979
D000082AcetaminophenPPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of PLEKHA1 mRNA]17585979
D020106AcrylamideAcrylamide results in increased expression of PLEKHA1 mRNA28959563
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of PLEKHA1 gene27153756
D006710HomocysteineHomocysteine results in decreased expression of PLEKHA1 mRNA17326132
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of PLEKHA1 mRNA"26238291
C543008bis(4-hydroxyphenyl)sulfone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of PLEKHA1 mRNA28628672
C006780bisphenol Abisphenol A affects the expression of PLEKHA1 mRNA21786754
C006780bisphenol A[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of PLEKHA1 mRNA28628672
C006780bisphenol Abisphenol A affects the expression of PLEKHA1 mRNA25181051
C584509C646 compoundC646 compound results in increased expression of PLEKHA1 mRNA26191083
D019256Cadmium ChlorideCadmium Chloride results in increased expression of PLEKHA1 mRNA26472689
D002251Carbon TetrachlorideCarbon Tetrachloride results in increased expression of PLEKHA1 mRNA25270620|2733941
D002737ChloropreneChloroprene results in increased expression of PLEKHA1 mRNA23125180
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of PLEKHA1 mRNA20938992
C074702chromium hexavalent ionchromium hexavalent ion affects the expression of PLEKHA1 mRNA28472532
D002994Clofibrate[Clofibrate co-treated with Acetaminophen] affects the expression of PLEKHA1 mRNA17585979
D002994ClofibratePPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of PLEKHA1 mRNA]17585979
D019327Copper SulfateCopper Sulfate results in increased expression of PLEKHA1 mRNA19549813
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of PLEKHA1 mRNA28628672
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of PLEKHA1 mRNA28628672
D002945CisplatinCisplatin results in increased expression of PLEKHA1 mRNA27392435
C036042dicyclohexyl phthalatedicyclohexyl phthalate affects the expression of PLEKHA1 mRNA26924002
D004026DieldrinDieldrin results in decreased expression of PLEKHA1 mRNA20584760
D004041Dietary FatsDietary Fats results in increased expression of PLEKHA1 mRNA19030233|2260994
D004041Dietary Fatsrimonabant inhibits the reaction [Dietary Fats results in increased expression of PLEKHA1 mRNA]19030233
D004147DioxinsDioxins affects the expression of PLEKHA1 mRNA20463971
D004997Ethinyl EstradiolEthinyl Estradiol results in decreased expression of PLEKHA1 mRNA28196854
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of PLEKHA1 mRNA20938992
D017313FenretinideFenretinide results in increased expression of PLEKHA1 mRNA28973697
D006861Hydrogen Peroxide[Hydrogen Peroxide co-treated with Theophylline] results in decreased expression of PLEKHA1 protein18951874
D006861Hydrogen PeroxideHydrogen Peroxide results in increased expression of PLEKHA1 mRNA18951874
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of PLEKHA1 mRNA28628672
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of PLEKHA1 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of PLEKHA1 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of PLEKHA1 mRNA28628672
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of PLEKHA1 mRNA20938992
C029938nickel sulfatenickel sulfate results in decreased expression of PLEKHA1 mRNA22714537
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of PLEKHA1 mRNA"25510870
C023036perfluorooctanoic acidperfluorooctanoic acid results in increased expression of PLEKHA1 mRNA19162173
D010634PhenobarbitalPhenobarbital affects the expression of PLEKHA1 mRNA19136022
C006253pirinixic acidpirinixic acid affects the expression of PLEKHA1 mRNA19136022
C006253pirinixic acidpirinixic acid results in decreased expression of PLEKHA1 mRNA17426115
C006253pirinixic acidpirinixic acid results in increased expression of PLEKHA1 mRNA23811191
C006253pirinixic acidpirinixic acid results in increased expression of PLEKHA1 mRNA19162173
D011441PropylthiouracilPropylthiouracil results in decreased expression of PLEKHA1 mRNA24780913
C089032rimonabantrimonabant inhibits the reaction [Dietary Fats results in increased expression of PLEKHA1 mRNA]19030233
C009277sodium arsenatesodium arsenate results in increased expression of PLEKHA1 mRNA23922661
C009277sodium arsenatesodium arsenate results in decreased expression of PLEKHA1 mRNA21795629
C017947sodium arsenitesodium arsenite affects the methylation of PLEKHA1 gene28589171
C004648testosterone enanthatetestosterone enanthate affects the expression of PLEKHA1 mRNA17440010
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of PLEKHA1 mRNA22298810
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of PLEKHA1 mRNA21570461
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of PLEKHA1 mRNA20959002
D013806Theophylline[Hydrogen Peroxide co-treated with Theophylline] results in decreased expression of PLEKHA1 protein18951874
D013893ThiramThiram results in increased expression of PLEKHA1 mRNA20530235
C009495titanium dioxidetitanium dioxide affects the expression of PLEKHA1 mRNA17656681
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHA1 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of PLEKHA1 mRNA26272509
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHA1 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of PLEKHA1 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of PLEKHA1 mRNA23179753|2627250
D014635Valproic AcidValproic Acid results in decreased methylation of PLEKHA1 gene29154799
D014635Valproic AcidValproic Acid results in increased expression of PLEKHA1 mRNA19101580|2317975
D014810Vitamin EVitamin E results in decreased expression of PLEKHA1 mRNA19244175
D024483Vitamin K 3Vitamin K 3 affects the expression of PLEKHA1 mRNA20044591

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI11802782  14516276  18654987  
GO:0030165PDZ domain binding-IBA21873635  
GO:0030165PDZ domain binding-IPI11802782  14516276  15485858  
GO:0035091phosphatidylinositol binding-IBA21873635  
GO:0043325phosphatidylinositol-3,4-bisphosphate binding-IDA11001876  17823121  
GO ID GO Term Qualifier Evidence PubMed
GO:0001553luteinization-IEA-  
GO:0006661phosphatidylinositol biosynthetic process-TAS-  
GO:0007283spermatogenesis-IEA-  
GO:0008209androgen metabolic process-IEA-  
GO:0008210estrogen metabolic process-IEA-  
GO:0009791post-embryonic development-IEA-  
GO:0014065phosphatidylinositol 3-kinase signaling-IDA12101241  
GO:0031529ruffle organization-IDA15485858  
GO:0033327Leydig cell differentiation-IEA-  
GO:0035264multicellular organism growth-IEA-  
GO:0045184establishment of protein localization-IDA14516276  
GO:0048008platelet-derived growth factor receptor signaling pathway-IEA-  
GO:0048705skeletal system morphogenesis-IEA-  
GO:0050853B cell receptor signaling pathway-IDA12101241  
GO:0051898negative regulation of protein kinase B signaling-IMP14516276  
GO:0060021roof of mouth development-IEA-  
GO:0060325face morphogenesis-IEA-  
GO:0070301cellular response to hydrogen peroxide-IDA14516276  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IDA-  
GO:0005654nucleoplasm-IDA-  
GO:0005737cytoplasm-IBA21873635  
GO:0005737cytoplasm-IDA12101241  14516276  
GO:0005829cytosol-IDA-  
GO:0005886plasma membrane-IDA12101241  14516276  
GO:0005886plasma membrane-TAS-  
GO:0016020membrane-IBA21873635  
GO:0032587ruffle membrane-IDA12101241  
GO:0070062extracellular exosome-HDA19056867  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismTAS
R-HSA-1483255PI MetabolismTAS
R-HSA-1483257Phospholipid metabolismTAS
R-HSA-1660499Synthesis of PIPs at the plasma membraneTAS
R-HSA-556833Metabolism of lipidsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
21197116Genome-wide association analyses of genetic, phenotypic, and environmental risks in the age-related eye disease study. (2010 Dec 17)Ryu EMol Vis
18097986Review of genetics in age related macular degeneration. (2007 Oct-Dec)Montezuma SRSemin Ophthalmol
18164066Alleles in the HtrA serine peptidase 1 gene alter the risk of neovascular age-related macular degeneration. (2008 Jul)Deangelis MMOphthalmology
18541031The NEI/NCBI dbGAP database: genotypes and haplotypes that may specifically predispose to risk of neovascular age-related macular degeneration. (2008 Jun 9)Zhang HBMC Med Genet
29565837Polymorphisms in Selected Genes and Their Association with Age-Related Macular Degeneration in a Chinese Population. (2018 Mar 22)Huang QMed Sci Monit